Recordati Industria Chimica e Farmaceutica SpA REC.VI
Last Updated: Aug 07, 12:00 AM·WBAG
REC.VI Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Recordati Industria Chimica e Farmaceutica SpA is classified as halal.
HALAL
Report Source: undefined Quarter Report
Recordati Industria Chimica e Farmaceutica SpA. Stock Analysis REC.VI
Austria Health Care Large Cap
Recordati SpA engages in the research, development, manufacture, and marketing of pharmaceuticals. The company is headquartered in Milan, Milano and currently employs 4,693 full-time employees. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.